Organized by

HELLENIC SOCIETY OF PERIOPERATIVE CARE

In Collaboration with

1ST DEPARTMENT OF OBSTETRICS AND GYNECOLOGY, NATIONAL & KAPODISTRIAN UNIVERSITY OF ATHENS, MEDICAL SCHOOL
DIRECTOR: G. DASKALAKIS



ADVANCED PERIOPERATIVE and critical care management in GYNECOLOGIC ONCOLOGY

FINAL PROGRAM

10 October 2026

Athens Capital Hotel

FREE REGISTRATION

GCP | GLOBAL EXCELLENCE LOCAL EXPERTISE

Avelle™

Negative Pressure Wound Therapy System

More moments that matter

Το σύστημα Avelle™ NPWT συνδυάζει την τεχνολογία επιθεμάτων AQUACEL® για έως και 30 ημέρες.

- Αποτελεσματική διαχείριση εξιδρώματος
- Προστασία χειρουργικών τομών και τραυμάτων
- Διακριτικό, ελαφρύ και εύκολο στη χρήση



Confidence in every next step

- POWERED BY AQUACEL® TECHNOLOGY
- UP TO 30 DAYS OF THERAPY
- LIGHTWEIGHT AND WEARABLE
- DESIGNED FOR CONTINUITY OF CARE

convatec
— forever caring —

People. Products. Possibilities.



WELCOME ADDRESS

Dear Colleagues,

It is our great pleasure to welcome you to the Scientific Meeting on "Advanced Perioperative and Critical Care Management in Gynecologic Oncology," to be held in Athens, Greece, on 10 October 2026, at the Athens Capital Hotel. This meeting is jointly organized by the Hellenic Society of Perioperative Care and the First Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens, bringing together leading clinicians, researchers, and allied healthcare professionals committed to advancing perioperative and critical care for women with gynecologic cancer. The optimization of perioperative care has become a cornerstone of contemporary surgical practice, with growing evidence demonstrating its pivotal role in improving patient outcomes, accelerating recovery, and reducing postoperative morbidity. In gynecologic oncology, where patients frequently undergo complex surgical procedures and require individualized multidisciplinary care, the integration of evidence-based perioperative pathways with modern critical care principles is essential for delivering high-quality, patient-centered treatment. Throughout this Scientific Meeting, experts will present the latest evidence and emerging concepts across the continuum of perioperative management, including preoperative optimization, anesthetic and intraoperative strategies, postoperative recovery pathways, critical care management, nutritional support, pain management, and the multidisciplinary coordination required for the care of high-risk surgical patients. Particular emphasis will be placed on translating current evidence into everyday clinical practice while identifying areas where further research and innovation are needed.

Beyond the scientific program, this meeting aims to foster meaningful discussion, collaboration, and the exchange of ideas among gynecologic oncologists, anesthesiologists, intensivists, perioperative physicians, nurses, midwives, physiotherapists, nutritionists, and other healthcare professionals dedicated to improving perioperative outcomes.

We are confident that your active participation will contribute significantly to the success of this meeting and to the continued advancement of perioperative and critical care in gynecologic oncology.

We look forward to welcoming you to Athens.

With our warmest regards,

Nikolaos Thomakos
Professor of Obstetrics & Gynaecology - Gynaecologic Oncology
National and Kapodistrian University of Athens (NKUA)



SCIENTIFIC PROGRAM

09:00-09:15	**WELCOME ADDRESS** **Prof. Georgios Daskalakis**
09:15-09:30	**OPENING REMARKS** **Prof. Nikolaos Thomakos**
09:30-11:00	**MORNING SESSION | PREOPERATIVE PREPARATION & PREVENTION** Chair: **Dimitrios Papatheodorou, George Vorgias**
09:30-09:45	Prevention of surgical complications with enhanced prehabilitation **Vasilios Pergialiotis**
09:50-10:05	Frailty & Pre-rehabilitation: Assessing the frailty of the gynecological oncological patient and preoperative optimization (anemia, nutrition) before major surgery **Dimitrios-Efthymios Vlachos**
10:10-10:25	Thromboprophylaxis & Oncology: An individualized approach to the prevention of Venous Thromboembolism (VTE) in high-risk procedures **Stamatios Petousis**
10:30-10:45	Advanced nutritional support: Beyond traditional thinking **Alexandros Tsigkas**
10:45-11:00	Discussion Commentator: **Emmanouil Kalampokas**
11:00-11:30	**Break**
11:30-12:40	**MIDDAY SESSION | SURGICAL GUIDELINES & CRITICAL CARE** Chairs: **Georgios Vlachos, Theodore Panoskaltsis, Petros Drakakis**
11:30-11:50	Ovarian Cancer Surgery / ESGO Ovarian Cancer Guidelines **Ane Gerda Zahl Eriksson**
12:00-12:15	Critical Care Management in Gynecological Oncology Surgery **Nikolaos Thomakos**
12:20-12:35	Advanced Hemodynamic Monitoring: Goal-Directed Fluid Therapy (GDFT) strategies during extensive cytoreductive surgeries **Effimia Evodia**
12:35-12:40	Discussion Commentator: **Emmanouel Stamatakis**



SCIENTIFIC PROGRAM

12:40-13:00	**Break**
13:00-14:30	**AFTERNOON SESSION | COMPLICATIONS & RECOVERY**
	Chairs: **Dimitrios Haidopoulos, Dimitrios Valsamidis**
13:00-13:15	Acute Kidney Injury (AKI) & Electrolyte Disturbances: The impact of fluids, medications, and intra-abdominal pressure on renal function **Kyriaki Kolovou**
13:20-13:35	Acid base disorders in the postoperative ICU. A practical approach to complex metabolic acidosis and alkalosis **Konstantina Kalopita**
13:40-13:55	Anastomotic Leak & Sepsis: Early clinical signs, imaging, and decision-making for re-operation vs. conservative management in the ICU **Pantelis Antonakis**
14:00-14:15	Pain Control & Mobilization: Unlocking functional recovery **Chrysoula Margioula-Siarkou**
14:15-14:30	Discussion Commentator: **Konstantinos Stroumpoulis**
14:30-15:30	**WORKSHOP - CASE PRESENTATION**
	Chairs: **Charalampos Theofanakis, Nikolaos Machairiotis**
	Participants: **Dimitrios Zouzoulas, Vasileios Lygizos, Ioannis Rodolakis, Kyveli Angelou, Athanasios Douligeris**
	Discussion Commentator: **Nikolaos Kathopoulis**

All presentations are followed by a brief Q&A session

diomed
ΙΑΤΡΙΚΑ ΠΡΟΪΟΝΤΑ ΑΕ


Ενδοδερμικό Συρραπτικό



Κόλλες Σύγκλισης Δέρματος
με και χωρίς Πλέγμα



Βιοαπορροφήσιμα Αιμοστατικά
Γάζα ή Σκόνη



Διαθερμίες & Πηγές Ενέργειας



Ψαλίδια Υπερήχων & RF
για Αγγεία έως 7mm



Εντοπισμένος Χειρουργικός
Φωτισμός



Πρόληψη & Αντιμετώπιση Παρενεργειών
από Ογκολογικές Θεραπείες



Ενθέματα Μαστού Silimed



4 Επιφάνειες, 4 Προβολές, 5 Σχήματα

Συστήματα Λιποαναρρόφησης
και Λιπομεταφοράς



3D Πλέγματα ADM Μαστού
Πλήρους Καλύψεως



Βιολογικά Πλέγματα ADM



3D Πλέγματα ADM Μαστού
Μερικής Καλύψεως



Ιθάκης 3 & Λ. Κηφισίας, 152 33 Χαλάνδρι, Αθήνα • Γράμμου 71, 151 24 Μαρούσι, Αθήνα
Τηλ.: 210 6847 024 • E-mail: info@diomed.gr

FACULTY

Angelou Kyveli	*Obstetrician-Gynecologist, Gynecological Oncologist, 1st Department of Obstetrics & Gynecology, "Alexandra" General Hospital, Athens, Greece*
Antonakis Pantelis	*Assistant Professor of Surgery, 2nd Department of Surgery, "Aretaieion" Hospital, National & Kapodistrian University of Athens, Athens, Greece*
Daskalakis Georgios	*Professor of Obstetrics and Gynecology Head of the 1st Dept. OB/GYN, NKUA, "Alexandra" Hospital, Vice President of the Hellenic Society of Obstetricians and Gynecologists, Vice President of the Hellenic Perinatal Society, Vice President of the Hellenic Society of Infectious Diseases in Obstetrics and Gynecology, Athens, Greece*
Douligeris Athanasios	*MD, MSc, PhD Senior Clinical Fellow of Gynecologic Endoscopy, 1st Department of Obstetrics & Gynecology, National & Kapodistrian University of Athens, "Alexandra" General Hospital, Athens, Greece*
Drakakis Petros	*Professor Emeritus of Obstetrics & Gynecology, Former Director of the 3rd Department of Obstetrics & Gynecology, National & Kapodistrian University of Athens (NKUA), "Attikon" University Hospital, Athens, Vice President, Hellenic Authority for Medically Assisted Reproduction (EAIYA), Athens, Greece*
Eriksson Zahl Ane Gerda	*MD, Phd, Professor, Head of Gynecologic Cancer, Department of Surgical Oncology, The Norwegian Radium Hospital, Oslo University Hospital Comprehensive Cancer Center (OUS-CCC), Institute for Clinical Medicine, Faculty of Medicine, University of Oslo (UiO), Norway*
Evodia Effimia	*Consultant Anaesthesiologist-Intensivist, Private Hospital "YGEIA HHG", "MITERA" Maternity & Gynecology Department, General Secretary of Hellenic Society of Anaesthesiology, Athens, Greece*
Haidopoulos Dimitrios	*Professor of Gynecologic Oncology, 1st Department of Obstetrics & Gynecology, National & Kapodistrian University of Athens, "Alexandra" General Hospital, Athens, Greece*
Kalampokas Emmanouil	*MSc, PhD, RCOG, RCOG/ ESGO, Consultant Gynecologist Oncologist, Assistant Professor, Medical School, University of Athens, Athens, Greece*
Kalopita Konstantina	*Consultant Anaesthetist, "Elena Venizelou" General & Maternity Hospital, Athens, Greece*
Kathopoulis Nikolaos	*Obstetrician-Gynecologist, Academic Fellow, 1st Department of Obstetrics & Gynecology, National & Kapodistrian University of Athens, Athens, Greece*
Kolovou Kyriaki	*Nephrologist - ICU Specialist, Assistant Professor of Organ Donation & Transplantation, 2nd Department of Critical Care Medicine, "Attikon" University Hospital, Athens Medical School, NKUA, Athens, Greece*
Lygizos Vasileios	*Academic Research Fellow, 1st Department of Obstetrics & Gynecology, Gynecologic Oncology Unit, "Alexandra" General Hospital, Athens, Greece*

FACULTY

Machairiotis Nikolaos	*Assistant Professor in Obstetrics & Gynecology, 3rd Department of Obstetrics & Gynecology, National & Kapodistrian University of Athens, "Attikon" University Hospital, Athens, Greece*
Margioula-Siarkou Chrysoula	*Assistant Professor of Obstetrics & Gynecology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece*
Panoskaltsis Theodoros	*MD, PhD, FRCOG, CCST (UK), ESPSO, ESGO, Associate Professor, Director, Gynecological Oncology Unit, "Iaso" General Hospital, Athens, Greece*
Papatheodorou Dimitrios	*Consultant Gynecologic Oncologist, Head of Gyn Dept, "Agios Savvas" Cancer Hospital, Athens, Greece*
Pergialiotis Vasilios	*Assistant Professor of Obstetrics & Gynecology, 1st Department of Obstetrics & Gynecology, National & Kapodistrian University of Athens, Athens, Greece*
Petousis Stamatios	*Assistant Professor of Obstetrics & Gynecology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece*
Rodolakis Ioannis	*Obstetrician-Gynecologist, Academic Fellow, 1st Department of Obstetrics & Gynecology, National & Kapodistrian University of Athens, "Alexandra" General Hospital, Athens, Greece*
Stamatakis Emmanouil	*Consultant Anesthesiologist, Athens, Greece*
Stroumpoulis Konstantinos	*MD, PhD, FEACL, Anesthesiology Dpt Head, "Elena Venizelou" General & Maternity Hospital, Athens, Greece*
Theofanakis Charalampos	*MD, PhD, Gynecologic Oncologist (ESGO), Assistant Professor of Obstetrics & Gynecology, 3rd Department of Obstetrics & Gynecology, National & Kapodistrian University of Athens, Athens, Greece*
Thomakos Nikolaos	*MD, PhD, Professor of Obstetrics & Gynecology &Gynecologic Oncology, National & Kapodistrian University of Athens, Athens, Greece*
Tsigkas Alexis	*Clinical Dietitian, MSc, ESPEN Diploma in Clinical Nutrition, Research Associate, Harokopio University of Athens, Athens, Greece*
Valsamidis Dimitrios	*Anesthesiologist, Clinical Director, Department of Anesthesiology, "Alexandra" General Hospital, Athens, Greece*
Vlachos Dimitrios-Efthymios	*Assistant Professor in Obstetrics & Gynecology, National & Kapodistrian University of Athens, Greece*
Vlachos Georgios	*Professor Emeritus of Gynecological Oncology, Athens, Greece*
Vorgias George	*MD, PhD, Gynae - Oncologist, "Metaxa" Memorial Cancer Hospital, Clinical Director of the Gynecological Dept., Greece*
Zouzoulas Dimitrios	*MSc, PhD, FEBS-BS, FESGO-EBCOG, Obstetrician - Gynecological Oncologist - Breast Surgeon, 1st Department of Obstetrics & Gynecology, Aristotle University of Thessaloniki, "Papageorgiou" Hospital, Greece*



SPONSORSHIPS

BIANEE A.E.
ΒΙΟΜΗΧΑΝΙΑ ΦΑΡΜΑΚΩΝ
ΕΤΑΙΡΕΙΑ ΤΟΥ ΟΜΙΛΟΥ ΓΙΑΝΝΑΚΟΠΟΥΛΟΥ

GCP
Dedicated to healthcare.

diomed
ΙΑΤΡΙΚΑ ΠΡΟΪΟΝΤΑ ΑΕ

LEO

MAVROGENIS
EMPOWERING HEALTH
35 YEARS

pelmyplus
MEDICAL



GENERAL INFORMATION

VENUE

Athens Capital Hotel
4 Eleftheriou Venizelou Avenue & 2 Kriezotou Street, Syntagma Square, 105 64 Athens, Greece
Tel: +30 214 444 2000

DATES

The Meeting will be held on Saturday, October 10, 2026.

LANGUAGE

The lectures of the Meeting will be delivered in English.

ACCREDITATION

The Meeting has been granted with 3 CME credits by the Hellenic Society of Obstetrics and Gynecology (HSOG).

ORGANIZED BY

HELLENIC SOCIETY OF PERIOPERATIVE CARE
PREPARE · OPTIMIZE · CARE

REGISTRATIONS

FREE PARTICIPATION

MEETING SECRETARIAT MD congress
Alex. Panagouli 118, 153 43 Agia Paraskevi, Athens, Greece, +30 210 607 4200
e-mail: md@mdcongress.gr site: www.mdcongress.gr

Medtronic



Ligasure™ XP
Maryland jaw sealer/divider

Take vessel sealing to the next level.

One-step and latching handle designs bring you to new levels of performance,[†,‡,‡,§] precision,[†,‡,‡] and procedural efficiency.[†,‡,Ω]

Get ready to experience the LigaSure™ XP Maryland jaw device.



† The LigaSure™ XP Maryland jaw device is indicated for use in general surgery and such surgical specialties as colorectal, bariatric, urologic, vascular, thoracic, and gynecologic. ‡ Compared to their current preferred device; 21 of 23 surgeons agreed during clinical procedures. § Thick tissue is defined as noninfected vascular tissue or fatty tissue. Ω Compared to their current preferred device; 20 of 23 surgeons agreed during clinical procedures. 1. Based on Inhenvo report #R0069574Ha Rev A, Product Introduction report: LigaSure™ XP Maryland jaw sealer/divider. May 2023. LigaSure™ XP Maryland jaw sealer/divider ©2023 Medtronic. Medtronic, Medtronic logo, and Engineering the extraordinary are trademarks of Medtronic. All other brands are trademarks of a Medtronic company.

MAVROGENIS
Authorized Distributor Medtronic


An. Mavrogenis S.A. 1A Gionas str., P.C.: 14451, Metamorfosi, Athens.
T: +30 210 20 20 232 - www.mavrogenis.com

NOTES

NOTES

NOTES

innohep®
tinzaparin sodium



Χορηγείται με ιατρική συνταγή.
Για πλήρεις συνταγογραφικές πληροφορίες επικοινωνήστε με την LEO Pharmaceutical Hellas S.A.

Για το ισχύον δελτίο τιμών των φαρμάκων της LEO Pharma σκανάρετε εδώ

LEO Pharmaceutical Hellas S.A
Παπανικολή 22Α, 15232, Χαλάνδρι
Τηλ: 212 222 5000
contact@leo-pharma.com
αρ. ΓΕΜΗ 117058301000

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και Αναφέρετε ΟΛΕΣ τις ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

L E O

Advancing the care of patients with thrombosis

© LEO Pharma copyright - GR_inn_adv_Nov_2024-MAT-71106.
All LEO Pharma trademarks mentioned belong to the LEO Pharma Group.

Ivor®
Bemiparin sodium

IvorMAX®
Bemiparin sodium



ΣΥΝΟΠΤΙΚΗ ΠΕΡΙΓΡΑΦΗ ΤΩΝ ΧΑΡΑΚΤΗΡΙΣΤΙΚΩΝ ΤΟΥ ΠΡΟΪΟΝΤΟΣ

ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ: Ivor 2.500 IU antiXa/0,2 ml ενέσιμου διαλύματος σε προγεμισμένες σύριγγες **ΠΟΙΟΤΙΚΗ & ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ:** Bemiparin sodium: 2.500 IU (anti Factor Xa*) ανά 0,2 ml προγεμισμένη σύριγγα (ισοδύναμη με 12.500 IU (anti Factor Xa*) ανά ml ενέσιμου διαλύματος). Η δραστικότητα περιγράφεται σε Διεθνείς μονάδες anti-Factor Xa δραστικότητας (IU) με βάση το Πρώτο Διεθνές Πρότυπο Αναφοράς Ηπαρίνης Χαμηλού Μοριακού Βάρους. Για τον πλήρη κατάλογο των εκδόχων, βλ. παράγραφο 6.1. **ΣΥΣΚΕΥΑΣΙΕΣ/ΤΙΜΕΣ:** IVOR 2.500 IU anti-Xa/0,2 ml BT x 2 PF.SYR Λ.Τ.: 5,83 €

ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ: Ivor 3.500 IU antiXa/0,2 ml ενέσιμου διαλύματος σε προγεμισμένες σύριγγες. **ΠΟΙΟΤΙΚΗ & ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ:** Bemiparin sodium: 3.500 IU (anti Factor Xa*) ανά 0,2 ml προγεμισμένη σύριγγα (ισοδύναμη με 17.500 IU (anti Factor Xa*) ανά ml ενέσιμου διαλύματος). Η δραστικότητα περιγράφεται σε Διεθνείς μονάδες anti-Factor Xa δραστικότητας (IU) με βάση το Πρώτο Διεθνές Πρότυπο Αναφοράς Ηπαρίνης Χαμηλού Μοριακού Βάρους. Για τον πλήρη κατάλογο των εκδόχων, βλ. παράγραφο 6.1. **ΣΥΣΚΕΥΑΣΙΕΣ/ΤΙΜΕΣ:** IVOR 3.500 IU anti-Xa/0,2 ml BT x 2 PF.SYR Λ.Τ.: 10,74 BT x 30 PF.SYR Λ.Τ.: 120,83 €

ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ: Ivormax 25.000 IU anti-Xa/ml ενέσιμου διαλύματος σε προγεμισμένες σύριγγες **ΠΟΙΟΤΙΚΗ & ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ:** Bemiparin sodium: 25.000 IU (anti-Factor Xa*) ανά ml ενέσιμου διαλύματος. Ισοδύναμη με: 5.000 IU (anti-Factor Xa) ανά 0,2 ml προγεμισμένη σύριγγα, 7.500 IU (anti-Factor Xa) ανά 0,3 ml προγεμισμένη σύριγγα, 10.000 IU (anti-Factor Xa) ανά 0,4 ml προγεμισμένη σύριγγα. * Η δραστικότητα περιγράφεται σε Διεθνείς μονάδες anti-Factor Xa δραστικότητας (IU) με βάση το Πρώτο Διεθνές Πρότυπο Αναφοράς Ηπαρίνης Χαμηλού Μοριακού Βάρους. Για τον πλήρη κατάλογο των εκδόχων, βλ. παράγραφο 6.1. **ΣΥΣΚΕΥΑΣΙΕΣ/ΤΙΜΕΣ:** IVORMAX 25.000 IU anti-Xa/ml, BTx2PF. SYRx0,2ML **Λ.Τ.: 23,40€** , IVORMAX 25.000 IU anti-Xa/ml, BTx2PF.SYRx0,3ML **Λ.Τ.: 26,43€** , IVORMAX 25.000 IU anti-Xa/ml BTx2PF.SYRx0,4ML **Λ.Τ.: 23,33€**

ΦΑΡΜΑΚΟΤΕΧΝΙΚΗ ΜΟΡΦΗ: Ενέσιμο διάλυμα σε προγεμισμένες σύριγγες. (Άχρωμο ή ελαφρώς κιτρινωπό, διαυγές διάλυμα, ελεύθερο ορατών σωματιδίων). ΚΑΤΟΧΟΣ ΤΗΣ ΑΔΕΙΑΣ ΚΥΚΛΟΦΟΡΙΑΣ: Προϊόν της LABORATORIOS FARMACEUTICOS ROVI S.A., ΙΣΠΑΝΙΑ. **Κάτοχος αδείας κυκλοφορίας:** BIANEΞ Α.Ε., Οδός Βαρυμπόμπης 8, 14671 Ν. Ερυθραία, Κηφισιά, Τηλ. 210800911. **ΑΡΙΘΜΟΣ(ΟΙ) ΑΔΕΙΑΣ ΚΥΚΛΟΦΟΡΙΑΣ:** 24481/26-02-2020, 24482/26-02-2020, 24483/26-02-2020.

ΗΜΕΡΟΜΗΝΙΑ ΑΝΑΘΕΩΡΗΣΗΣ ΤΟΥ ΚΕΙΜΕΝΟΥ: 06-04-2023 (Ivor), 12-07-2023 (Ivormax)

ΤΡΟΠΟΣ ΔΙΑΘΕΣΗΣ: Φαρμακευτικό προϊόν για το οποίο απαιτείται ιατρική συνταγή

Περαιτέρω πληροφορίες διατίθενται από τον ΚΑΚ κατόπιν αιτήσεως.

BIANEΞ Α.Ε.
ΒΙΟΜΗΧΑΝΙΑ ΦΑΡΜΑΚΩΝ
ΕΤΑΙΡΕΙΑ ΤΟΥ ΟΜΙΛΟΥ ΓΙΑΝΝΑΚΟΠΟΥΛΟΥ

BIANEΞ Α.Ε. - Έδρα : Οδός Βαρυμπόμπης 8, 14671 Ν. Ερυθραία, Κηφισιά
Ταχ. Θυρίδα 52894, 146 10 Ν. Ερυθραία • Τηλ. : 210 8009111• Fax: 210 8071573
E-mail: mailbox@vianex.gr • WEBSITE: www.vianex.gr
ΘΕΣΣΑΛΟΝΙΚΗ: Ακαδήμου 113, 562 24 Εύοσμος Θεσσαλονίκης • Τηλ.: 2310 861683
ΑΡ. Γ.Ε.ΜΗ. 000274201000

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και Αναφέρετε ΟΛΕΣ τις ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

VE-24236-IVO-9/2024